1270800

氟卡尼 乙酸盐

United States Pharmacopeia (USP) Reference Standard

• 别名: N -（2-哌啶基甲基）-2,5- 双 -（2,2,2-三氟乙氧基）苯甲酰胺 乙酸盐
• 经验公式（希尔记法）: C₁₇H₂₀F₆N₂O₃ · C₂H₄O₂
• CAS号: 54143-56-5
• 分子量: 474.39
• MDL號碼: MFCD00214290
• 分類程式碼代碼: 41116107
• PubChem物質ID: 329749848
• NACRES: NA.24

属性

• 等級: pharmaceutical primary standard
• API 家族: flecainide
• 製造商／商標名: USP
• 應用: pharmaceutical (small molecule)
• 格式: neat
• 儲存溫度: 2-8°C
• SMILES 字串: CC(O)=O.FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC2CCCCN2
• InChI: 1S/C17H20F6N2O3.C2H4O2/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11;1-2(3)4/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26);1H3,(H,3,4)
• InChI 密鑰: RKXNZRPQSOPPRN-UHFFFAOYSA-N
• 基因資訊: human ... SCN5A(6331)

说明

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

應用

• Advanced Drug Delivery for Tuberculosis Treatment: Flecainide acetate is integral in developing inhalable porous particles, demonstrating effective lung drug delivery systems for treating tuberculosis. This novel application optimizes the therapeutic index of antituberculosis medications, minimizing systemic side effects while maximizing pulmonary uptake (Campos Pacheco et al., 2024).


• Cardiac Arrhythmia Management: Flecainide acetate, known for its role in arrhythmia management, has been studied for its efficacy following patent foramen ovale closure. The drug′s mechanism as a sodium channel inhibitor makes it a pivotal agent in preventing atrial fibrillation post-surgery, enhancing patient recovery and long-term cardiac health (Apostolos et al., 2024).


• Genetic Research on Arrhythmias: Flecainide acetate is used in genetic models to establish a life-threatening arrhythmia model by screening mutagenized mice. This research aids in identifying genetic predispositions to arrhythmias, paving the way for targeted therapies that modify disease progression and improve patient outcomes (Okabe et al., 2024).


• Electrophysiological Studies: Flecainide acetate′s properties as a class 1C antiarrhythmic agent are utilized in clinical electrophysiology to assess and refine therapeutic strategies for ventricular complex suppression in nonischemic cardiomyopathy. This application underlines its importance in detailed cardiac function studies and therapy optimization (Ruskin et al., 2024).


• Toxicology and Safety Profiling: Research on the potential pitfalls in using hypertonic sodium bicarbonate for treating cardiac toxic drug poisonings, where flecainide acetate is involved, underscores the complexity of managing drug-induced cardiac emergencies. This study provides crucial insights into safer, more effective antidotal therapies (Chan and Buckley, 2024).

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

安全信息

• 象形圖: GHS08,GHS07
• 訊號詞: Danger
• 危險聲明: H302,H315,H319,H335,H360FD
• 防範說明: P202 - P261 - P301 + P312 - P302 + P352 - P305 + P351 + P338 - P308 + P313
• 危險分類: Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3
• 標靶器官: Respiratory system
• 儲存類別代碼: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable